We investigated the pattern of lipoprotein lipase (LPL) expression in B-cell chronic lymphocytic leukemia (B-CLL) and assessed its prognostic relevance. Expression of LPL mRNA as well as protein was highly restricted to leukemic B cells. The intensity of intracellular immunoreactivity of LPL was higher in samples of patients with unmutated immunoglobulin heavychain variable region genes (IGV H ) compared to those with mutated IGV H genes. LPL mRNA levels in peripheral blood mononuclear cells (PBMNC) from 104 CLL patients differed by 1.5 orders of magnitude between cases with mutated (N ¼ 51) or unmutated (N ¼ 53) IGV H (median: 1.33 vs 45.22 compared to normal PBMNC). LPL expression correlated strongly with IGV H mutational status (R ¼ 0.614; Po0.0001). High LPL expression predicted unmutated IGV H status with an odds ratio of 25.90 (Po0.0001) and discriminated between mutated and unmutated cases in 87 of 104 patients (84%). LPL expression was higher in patients with poor risk cytogenetics. High LPL expression was associated with a shorter treatment-free survival (median 40 vs 96 months, P ¼ 0.001) and a trend for a shorter median overall survival (105 months vs not reached). Our data establish LPL as a prognostic marker and suggest functional consequences of LPL overexpression in patients with B-CLL.
Introduction
The prognosis of patients with B-cell chronic lymphocytic leukemia (B-CLL) is still determined by the clinical staging systems of Binet and Rai. [1] [2] [3] [4] Unfortunately, these systems fail to identify patients in early stages whose disease will rapidly progress. In search for additional prognostic factors, several parameters have shown relevance: lymphocyte doubling time, LDH, serum b2-microglobulin, soluble CD23, serum thymidine kinase, expression of CD38, cytogenetic aberrations and mutational status of immunoglobulin heavy-chain variable region genes (IGV H ). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] IGV H mutational status is currently the best predictor of outcome independent of clinical stage. [13] [14] [15] However, DNA sequencing is not available for routine diagnostics.
More recently, molecular research has identified a considerable number of genes differentially expressed in B-CLL. 20, 21 One of these genes, the 70 kDa T-cell receptor z-chain-associated protein tyrosine kinase (ZAP-70), was discovered by gene expression profiling and has subsequently been shown to predict IGV H mutational status and prognosis in CLL. [22] [23] [24] [25] [26] [27] Determination of ZAP-70 by FACS analysis is currently the best alternative for V H gene sequencing. 24, 27 On the other hand, assessment of ZAP-70 by real-time PCR requires B-cell sorting in order to avoid false-positive results by contaminating T cells.
RNA expression of activation-induced cytidine deaminase (AID), which is essential for somatic hypermutation of immunoglobulin genes was also associated with IGV H mutational status in most studies. [28] [29] [30] [31] However, its levels are generally low. In addition, determination of AID by quantitative PCR resulted in a considerable number of discordant results, particularly at intermediate expression levels. 31 Interestingly, lipoprotein lipase (LPL) was among the most differentially expressed genes reported in the initial profiling studies by Rosenwald and Klein. 20, 21 LPL plays a central role in lipid metabolism and catalyzes the hydrolysis of chylomicrons and very-low-density lipoproteins. Additional noncatalytic binding functions lead to increased accumulation and cellular uptake of lipoproteins. 32, 33 LPL is normally expressed in adipose tissue, cardiac and skeletal muscles, and lactating mammary gland. Lower levels are produced by macrophages, hormone-producing cells in the adrenals and ovaries, certain neuronal cells, thoracic aorta, spleen, testes, lung and kidney. 32 Activation of LPL occurs during differentiation of monocytes into macrophages and involves cytokine regulation. 32, 34 However, expression of LPL in B-CLL seems puzzling and its potential function in leukemic cells is not understood. At this time, only microarray data on LPL in CLL are published. In a recent abstract, Vasconcelos et al reported that a combination of LPL and ADAM29 assessed by real-time PCR can be used as a surrogate marker for IGV H mutational status (Vasconcelos et al. Leukemia Lymphoma 2003; 44: 29; abstract). However, many questions regarding LPL as a prognostic factor in CLL remain to be answered. In particular, expression of LPL protein in B-CLL cells has not been investigated to date.
Here, we report the validation of LPL as a diagnostic target in a well-characterized cohort of B-CLL patients. We investigated LPL mRNA expression by real-time PCR in unsorted peripheral blood mononuclear cells (PBMNC) from 104 patients with B-CLL in whom IGV H mutational status and cytogenetics were known. In this experimental setting, LPL correlates with IGV H mutational status, constituting an excellent alternative for ZAP-70 measurement by FACS. When analyzed with regard to patient outcome, LPL mRNA expression was significantly associated with treatment-free survival (TFS). In addition, we provide the first data on LPL protein showing that expression is very much restricted to CD19
þ CLL B cells, and that the pattern and intensity of expression differ between unmutated and mutated patient samples. Our data suggest that LPL is a reliable marker in B-CLL. LPL protein expression indicates consequences for the functional behavior of B-CLL cells.
Patients and methods

Patients
In all, 104 B-CLL patients (59 male, 45 female, median age 63 years) in various Binet stages (61 Binet A, 22 Binet B, 21 Binet C) diagnosed at the Division of Hematology at the Medical University of Vienna (55 patients, median observation time ¼ 42 months) or at the University of Ulm (49 patients, median observation time ¼ 50 months) were included in the present study after informed consent was obtained. The median observation time of the combined cohort was 48 months. All patients had a sustained lymphocytosis (more than 5 Â 10 9 /l) and a CD19 þ /CD5 þ /CD23 þ B-cell clone. The majority of patients (n ¼ 78) were untreated at the time of blood collection. IGV H mutational status and cytogenetics were known in all patients. Over time, 20 patients have died and a total of 55 patients were treated with various therapeutic regimens, mainly chlorambucil and fludarabine. Information on TFS was incomplete in two patients.
Determination of IGV H mutational status
IGV H mutational status was determined at the University of Ulm as described previously. 15 
Real-time PCR
All 104 patient samples were measured in the Vienna lab. RNA and cDNA were prepared from unsorted frozen PBMNC using RNA-Beet (Tel-Test Inc., Friendswood, TX, USA) and firststrand cDNA Synthesis kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
Real-time PCR was performed with the ABI Prism 7000 Sequence Detector (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions as described previously. 31 PCR was carried out in a 25 ml reaction volume using 1 ml of a 1:10 cDNA dilution with LPL-specific primers (designed from sequences in exons 6 and 7, Assays-on-Demand Gene Expression system, Applied Biosystems), probe and TaqMan s Universal Master Mix without AmpErase s UNG. All samples were run in duplicates. The LPL expression levels given in this study represent the mean value of these two independent measurements. The mean LPL expression of peripheral blood samples of two healthy donors was used as a calibrator for relative quantification. In addition to PBMNC, quantification of LPL was performed in CD19 þ -sorted B cells of three healthy donors, CD3
þ -sorted T cells of a healthy donor, the B-cell line Ramos, the T-cell line Jurkat, a myeloid cell line (K562), bone marrow, adipose tissue, spleen, kidney and other controls. RNA of adipose tissue, kidney and spleen was obtained from BD Biosciences Clontech (Palo Alto, CA, USA).
In addition, CD19 þ -sorted B cells (more than 98% purity in FACS analysis) from seven CLL patients and the remaining CD19 À cell fraction were investigated.
Conventional RT-PCR
Validation of real-time data by conventional RT-PCR was performed using primers designed from sequences in exons 7 and 9 (LPL forward:
Adipose tissue and 10 patient samples (five unmutated and five mutated) were selected for assay validation. Denaturing, annealing and extension steps were performed at 941C for 30 s, 601C for 30 s and 721C for 30 s, respectively, for 40 cycles including an initial 4 min denaturation step at 941C and a final extension step at 721C for 7 min. A measure of 10 ml of each PCR product was run on 1% agarose gel and visualized under UV light after ethidium bromide staining.
Surface and intracellular analysis of LPL protein
For surface expression of LPL, PBMC or purified B cells were washed with PBS and resuspended in PBS/BSA (0.3% BSA and 0.1% Na-azide). Nonspecific binding was blocked by 20% AB serum in PBS/BSA. Mouse monoclonal anti-LPL antibody 5D2 (a kind gift from J Brunzell, University of Washington) previously described by Peterson et al 35 was added and cells were incubated on ice for 30 min. Cells were washed in PBS/BSA and incubated with Alexa Fluor s 488-labeled goat anti-mouse antibody (Molecular Probes, Leiden, the Netherlands) diluted 1:400 for 30 min/41C in dark. Cells were washed and resuspended in PBS/BSA/Na-azide for FACS analysis. Double staining was performed using anti-LPL antibody together with phycoerythrin-conjugated anti-CD3, anti-CD14 or anti-CD19 antibodies to detect LPL on T cells, monocytes and B cells, respectively. Samples were analyzed using Becton Dickinson FACScan with Cell Quest Pro software. In all, 10 000 events were acquired and negative controls were included in each experiment by omitting the first antibody and by using nonimmune mouse IgG.
For intracellular detection of LPL, indirect immunofluorescence technique was performed using mAb anti-LPL, 5D2 antibody. Staining was performed on blood smears and PBMNC dropped on adhesion slides (Marienfeld, Germany). Cells were fixed with 3.7% formaldehyde in PBS for 10 min at room temperature. Preparations were washed two times with PBS (5 min each wash). Nonspecific binding was blocked by 20% AB serum in PBS for 20 min at room temperature. After two washes in PBS, cells were permeabilized with 0.1% Triton X-100 in PBS for 10 min and washed twice in PBS. Preparations were incubated with anti-LPL antibody in PBS/BSA overnight at 41C. After two washes in PBS, preparations were incubated with Alexa Fluor s 488-or Alexa Fluor s 594-labeled goat anti-mouse antibody for 45 min/room temperature in dark. After three washes in PBS, preparations were evaluated by fluorescence microscopy.
Fluorescence in situ hybridization (FISH)
Relevant genetic aberrations were assessed by FISH in 104 patients as described. 9 
Statistical analysis
Association between LPL and mutational status is described using the Spearman correlation coefficient, also partialized for Binet or Rai stages, respectively, as well as the origin of the patient sample (Vienna, Ulm). The 95% confidence intervals for these coefficients are computed via bootstrap-generated quantiles, after transforming the Spearman correlations by the inverse tanh-function for variance stabilization. 36 The association between LPL and various other variables is described by the Spearman correlation coefficients. Owing to the exploratory character of these tests, no correction for multiplicity has been performed here. The potency of LPL to predict the dichotomized mutational status was assessed using logistic regression, where LPL is dichotomized at the above cutoff value, and described by crude and adjusted odds ratios and their respective 95% profile likelihood confidence intervals, where adjustment refers to Binet or Rai stages, respectively. Owing to separation problems in the multiple models with dichotomized LPL, the FL macro as described in Heinze and Schemper 37 for logistic regression with Firth correction was used. As an alternative, a stepwise selection procedure has been applied where the dichotomized LPL and the above variables for adjustment are offered as potential effects. P-values p0.05 were considered to be statistically significant. All analyses have been performed using SAS Version 8.2 (SAS Institute Inc., Cary, NC, USA, 2001).
Analysis of overall survival (OS) and TFS using Kaplan-Meier estimation and log-rank statistics was performed using GraphPad Prism 3.0.
Results
Expression of LPL mRNA in controls and B-CLL
LPL mRNA expression was determined in various cell lines and tissues (Table 1) . Normal PBMNC was used as a reference with an expression level of one. The highest LPL expression was found in adipose tissue. In order to determine the origin of LPL RNA in B-CLL, we investigated CD19 þ -sorted B cells (98.5% purity) of a patient with high LPL levels (#45). High LPL expression was found in the CD19 þ fraction (2013), while the CD19 À PBMNC fraction expressed very low levels (0.7), indicating that LPL is indeed mainly produced in the leukemic cells. Similar results have been shown in another four patients with high LPL expression (median LPL expression of the CD19 þ fraction ¼ 340.3; median LPL expression of the CD19 À fraction ¼ 9). Two patients with low LPL levels had very low LPL expression in the CD19 þ cell fraction as well as in the CD19 À fraction (#1 and 2; not shown). The lymphoid cell lines Ramos (B) and Jurkat (T) tested negative, while LPL was detectable in K562 (myeloid). Interestingly, no or very low expression was found in CD19 þ -sorted B cells of three healthy donors (two tested negative, one with 0.06). Low expression (0.06) was also found in CD3 þ -sorted T cells.
LPL was detected with a distribution range covering 5 orders of magnitude (0-to 1924-fold) ( Table 1 ).
LPL expression and IGV H mutational status
In all, 53 of 104 patients (51%) tested had unmutated IGV H genes (defined by more than 98% homology to the best matching V H ), while 51 samples were mutated. As shown in Figure 1 unmutated cases had higher relative LPL levels (median ¼ 45.22, range 0-1924.14) than mutated cases (median ¼ 1.33, range 0-63.12). A strong correlation between individual LPL expression levels and mutational status was found (R ¼ 0.614; Po0.0001). A cutoff value of 10 provided the best degree of discrimination. Using this discrimination level, 87 of 104 patients (84%) could be classified correctly into the mutated or unmutated subgroups, respectively. This cutoff value was used for further calculation of odds ratio and clinical outcome.
LPL expression was able to predict unmutated IGV H status with an odds ratio of 25.90 (CI: 9.63, 79.87; Po0.0001). Significance was retained after adjustment for Rai and Binet stages, and importantly, the origin of the patient sample (Vienna or Ulm).
LPL and other prognostic factors
There was no correlation with the clinical Binet and Rai stages.
Multivariate analysis: When compared with Rai and Binet stages in a stepwise selection procedure, LPL was the only variable selected as a predictor of IGV H mutational status.
Cytogenetic aberrations
The distribution of cytogenetic subgroups within mutated and unmutated CLL cases was in line with previous observations. 14 In all, 22 of 33 patients with a deletion in 13q as the sole abnormality, 14 of 28 with a normal karyotype, six of 14 with a trisomy 12 (without a loss of p53 or a deletion in 11q) and one of 
OS and TFS
While the median OS in patients with LPL expression of more than 10 was 105 months, the median OS was not reached in the low LPL group (Figure 2a) . While this survival curve showed a clear trend, the difference between the two groups was not statistically significant. Importantly, high LPL expression (X10) was significantly associated with a short TFS (median 40 vs 96 months, P ¼ 0.001) (Figure 2b ). We also analyzed this cohort of patients with regard to mutational status. The median OS of the unmutated subgroup was identical to that of the high LPL group (105 months). However, the difference between mutated and unmutated patients was significant (P ¼ 0.002) due to the fact that less patients from the mutated group died within the first 3 years compared to patients with low LPL (Figure 2c ). Similar results were obtained for TFS (Figure 2d ).
Conventional RT-PCR
In order to validate the data obtained with real-time PCR, we designed conventional RT-PCR primers from sequences in exons 7 and 9 ( Figure 3 ), which were used to investigate selected cases. The highest LPL expression was found in adipose tissue. Strong LPL expression was found in five unmutated B-CLL samples, and no or very low LPL in five mutated B-CLL samples. These data confirm the results obtained by our real-time PCR assay.
Surface and intracellular expression of LPL protein
To get insight into the expression pattern of LPL at the protein level, PBMNC and blood smears of 22 patients (nine mutated and 13 unmutated) were evaluated by flow cytometry for surface expression and by indirect immunofluorescence for intracellular LPL.
Surface expression: By flow cytometry, the mean percentage of LPL þ CD19 þ cells within PBMNC was 8876, which corresponded to the percentage of the leukemic cells
in the respective patients and represented 498% of the CD19 þ B cells. A representative experiment from patient #48 is demonstrated in Figure 4A . The mean fluorescence intensity of LPL staining on CD19 þ cells was only slightly lower in patients with mutated compared to unmutated IGV H genes (2797110 vs 3267135, respectively). This indicates that the surface expression of LPL may not correspond to the expression of LPL at the mRNA level.
LPL was expressed on none or only on a small number of T cells (o0.8% of PBMNC were CD3 þ /LPL þ ). LPL was detected on monocytes and o2% of PBMNC coexpressed CD14 and LPL. The expression of LPL on CD14 þ cells was variable and 18-100% of CD14 þ cells were positive for LPL. Taking in consideration that, in B-CLL, T cells and monocytes represented In order to compare the LPL protein expression, unmutated (LPL mRNA high) and mutated (LPL mRNA low) samples from 10 patients (five mutated: #1, 10, 15, 24, 28 and 5; unmutated: #30, 42, 48, 52, 54) were prepared and stained under identical conditions. The intensity of intracellular immunoreactivity to LPL antibody in B-CLL cells was higher in each unmutated compared to the mutated samples. A representative example is shown in Figure 4c .
Discussion
LPL is a strong predictor of IGV H mutational status in unsorted PBMNC
Our study shows a strong correlation of LPL with IGV H mutational status in unsorted PBMNC. LPL is an ideal target with low background because of its absence in CD19 þ -sorted normal B cells as well as its low expression in PBMNC and CD3 þ -sorted T cells. On the other hand, our investigation of CD19 þ and CD19 À cells from B-CLL patients showed restriction of LPL to leukemic cells.
The discriminating threshold of 10 allowed classification into the mutated or unmutated subgroups in 84% of patients. The positive predictive value of LPL (43 of 49 high-expressing samples were unmutated ¼ 88%) as well as its negative predictive value (44 of 55 low-expressing samples were mutated ¼ 80%) are comparable with the numbers observed by FACS analysis of ZAP-70, the current gold standard (71% of unmutated patients ZAP-70 positive, 83% of mutated patients ZAP-70 negative). 
LPL is a prognostic factor in B-CLL
The close relationship to IGV H mutational status suggests a potential role of LPL as a prognostic factor by itself. Indeed, the significant association of high LPL to a shorter TFS (Figure 2b ) in our extended patient cohort indicates that LPL is also a prognostic factor in CLL. This is supported by the OS curve, which was not significant in our patients, but showed a clear trend toward a shorter survival of high LPL expressors.
We also analyzed LPL expression in different cytogenetic subgroups. High LPL levels were found in patients with unfavorable cytogenetic aberrations (loss in p53, deletion in 11q) in contrast to low levels in good risk cytogenetics (normal karyotype, deletion in 13q as the sole abnormality), fitting with the hierarchical model of genomic aberrations. 9 The correlation of LPL with IGV H mutational status retained significant after adjustment for clinical stages (Rai, Binet) , indicating that LPL is an independent predictor of IGV H mutational status.
LPL protein is expressed in B-CLL cells
The pattern of expression of LPL on the cell surface and in the cytoplasm of B-CLL cells, together with the expression of LPL mRNA, suggest that the leukemic cells are able to synthesize LPL and to capture this enzyme on the cell surface. However, the possible contribution of LPL internalization upon binding to a cell surface receptor remains to be clarified.
In fact, by immunofluorescence, we observed a clear difference in the intensity of cytoplasmic staining between high and low LPL mRNA expressors (unmutated and mutated cases). The magnitude of the difference in LPL mRNA expression between the two groups of patients (mutated vs unmutated) as assessed by real-time PCR was higher than the difference in the intensity of intracellular LPL protein staining. This may point to a multistep regulation of LPL synthesis, post-translational regulation or protein stability.
The functional role of LPL and the molecular mechanisms regulating its synthesis, the receptors on the cell surface as well as its relationship to ZAP-70 are currently unknown. However, it is possible that LPL might play an important role in fatty acid metabolism and energy supply to B-CLL cells. Hence, LPL could be critical for proliferation and survival of the leukemic cells. These issues are currently under investigation in our laboratories. In addition, a large-scale screening assay such as flow cytrometic analysis for intracellular LPL needs to be developed in order to make LPL measurement available for a large number of patients as was recently shown for ZAP-70 by Orchard et al.
27
In conclusion, we provide evidence that LPL mRNA expression correlates with IGV H mutational status and TFS and can therefore be considered as a valuable prognostic marker in B-CLL, with potential pathophysiological relevance to the disease.
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